ArticleJournal of neuro-oncology2010
Clinical and epidemiological characteristics of pediatric gliosarcomas.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Pediatric gliosarcoma, a rare central nervous system tumor in children: Case report and literature review.Heliyon · 2023Article
- Article
- Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.BMC pediatrics · 2021Review
- Retrobulbar chlorpromazine injection in a child with gliosarcoma invasion into the orbits.BMJ case reports · 2020Article
- Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.Frontiers in oncology · 2020Article
- Primary pediatric cerebellar gliosarcoma.Surgical neurology international · 2020Article
- Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.Journal of neuro-oncology · 2016Article
- Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015Article
- Therapeutic management of gliosarcoma in the temozolomide era.CNS oncology · 2015Review
- Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Journal of pediatric hematology/oncology · 2014Article
- Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Clinical and molecular characteristics of congenital glioblastoma.Neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliosarcoma (GS) is a glioblastoma with a sarcomatous component that is presumed to be a metaplastic differentiation of glioma cells. We studied the clinical relevance of this histological glioblastoma subentity within the pediatric population. We obtained patient data from the German HIT-GBM database, which contains clinical data for more than 600 pediatric patients with centrally reviewed high-grade gliomas. By applying defined inclusion criteria (diagnosis of GS proven by central neuropathological review; patient age 0 to 21 years), four patients were identified. In addition, after a review of the English medical scientific literature, 19 additional cases were found. The relative frequency of GS in the German HIT-GBM database was only 1.9%. In the whole series of 23 pediatric GS patients, including previously reported cases, the male-to-female-ratio was 1.2:1. GS was found in all pediatric age groups with a median age of 11 years, but there was an unexpectedly high accumulation in infants (6 of 23 <3 years of age, 26%). GS showed a strong predilection of the cerebral hemispheres (22 out of 23 cases). Increased intracranial pressure was the leading symptom of a short clinical history with a median duration of 0.7 month. Interestingly, six patients (26%) were reported with a history of cranial radiotherapy prior to GS diagnosis. In 60% of the GS patients in our series, gross total resection was achieved. Median overall (OS) and event-free survivals (EFS) of the total cohort were 12.1 and 9.8 months, respectively. In conclusion, GS is a very rare tumor entity in children. Literature review suggests a relatively higher incidence in infants and in patients with a previous history of radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.